Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma

This study aimed at determining the recommended dose of the mammalian target of rapamycin inhibitor everolimus in combination with mitomycin C (MMC) in patients with previously treated metastatic esophagogastric cancer. In this phase I trial, patients received escalated doses of oral everolimus (5,...

Descripción completa

Detalles Bibliográficos
Autores principales: Werner, Dominique, Atmaca, Akin, Pauligk, Claudia, Pustowka, Anette, Jäger, Elke, Al-Batran, Salah-Eddin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2013
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699844/
https://www.ncbi.nlm.nih.gov/pubmed/23930209
http://dx.doi.org/10.1002/cam4.77

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699844/
https://www.ncbi.nlm.nih.gov/pubmed/23930209
http://dx.doi.org/10.1002/cam4.77

Ejemplares similares